- Home
- DERM vs BCAB Comparison
DERM vs BCAB Comparison
Compare DERM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- BCAB
- Stock Information
- Founded
- DERM 2014
- BCAB 2007
- Country
- DERM United States
- BCAB United States
- Employees
- DERM N/A
- BCAB N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- DERM Health Care
- BCAB Health Care
- Exchange
- DERM Nasdaq
- BCAB Nasdaq
- Market Cap
- DERM 107.0M
- BCAB 101.0M
- IPO Year
- DERM 2021
- BCAB 2020
- Fundamental
- Price
- DERM $5.20
- BCAB $1.39
- Analyst Decision
- DERM Strong Buy
- BCAB Buy
- Analyst Count
- DERM 3
- BCAB 2
- Target Price
- DERM $9.50
- BCAB $5.00
- AVG Volume (30 Days)
- DERM 145.7K
- BCAB 1.1M
- Earning Date
- DERM 11-12-2024
- BCAB 11-07-2024
- Dividend Yield
- DERM N/A
- BCAB N/A
- EPS Growth
- DERM N/A
- BCAB N/A
- EPS
- DERM N/A
- BCAB N/A
- Revenue
- DERM $57,771,000.00
- BCAB $11,000,000.00
- Revenue This Year
- DERM N/A
- BCAB N/A
- Revenue Next Year
- DERM $37.38
- BCAB N/A
- P/E Ratio
- DERM N/A
- BCAB N/A
- Revenue Growth
- DERM N/A
- BCAB N/A
- 52 Week Low
- DERM $2.85
- BCAB $1.14
- 52 Week High
- DERM $8.11
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- DERM 43.96
- BCAB 32.90
- Support Level
- DERM $5.00
- BCAB $1.46
- Resistance Level
- DERM $5.60
- BCAB $2.53
- Average True Range (ATR)
- DERM 0.45
- BCAB 0.24
- MACD
- DERM -0.04
- BCAB -0.08
- Stochastic Oscillator
- DERM 14.98
- BCAB 5.02
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.